Stem Cells Market Size Worth $17.9 Billion By 2027 | CAGR: 8.2%

The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%, according to a new report by Grand View Research, Inc. Recent advances in tissue engineering strategies hold the potential to draw attention to the treatment of several chronic disorders. Moreover, automation in adult and cord blood processing and storage is expected to drive market growth significantly.

The development of banking facilities and resultant enhancement of stem cell production, storage, and characterization are also expected to enhance the volumetric capabilities of this therapy, globally. This would lead to revenue generation in the global market.

Regenerative medicine and cellular therapies are considered to transform the healthcare industry in a few years. Therefore, key players are focused on developing advanced therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, degenerative eye disorders, cancer, and stroke. Most of these therapies are under clinical trials and are expected to be launched soon.

Furthermore, the presence of a strong, diverse clinical pipeline is expected to accelerate revenue generation in the global market. Easy access to data through genomic, proteomic, and EHR databases has encouraged companies to investigate various therapies to aid in the treatment of previously untreatable conditions.

 To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/stem-cells-market

Further key findings from the report suggest:

• Adult stem cells (ASCs) segment occupied the largest share of the products in 2019 and is expected to maintain its dominance across the analysis period

• Factors such as long term renewal property, low rejection rates, and minimal ethical concerns associated with the utility of ASCs are attributive towards larger market share

• The regenerative medicine segment accounted for the largest share of owing to a huge pipeline for regenerative medicine products

• The cell acquisition technology segment occupied a major revenue share and is anticipated to witness the fastest CAGR over the forecast period owing to a rise in the number of research projects that require the application of cell harvesting technologies

• Allogenic therapy is the most commonly adopted therapy owing to its graft-versus-cancer response in cancer treatment and graft-versus-host response in organ or tissue transplant

• These responses allow allogenic stem cells to kill the cancer remaining after drug therapy and to prevent organ rejection and other complications post-surgery

• Presence of major companies, extensive government funding, and increasing research have contributed to the largest market share in North America

• The Asia Pacific region is expected to grow at a lucrative pace owing to strong product pipelines in regenerative therapies and large patient population

• Osiris Therapeutics Inc; BIOTIME, INC.; Celgene Corporation; STEMCELL Technologies Inc.; and Cynata are some of the key players operating in the stem cells market.

• The key players are undertaking strategic initiatives to maintain their market share. They are keen to seek investment from other bodies and also collaborate with other pharmaceutical giants. This is set to enhance market growth over the forecast period.

Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:

Stem Cells Product Outlook (Revenue, USD Million, 2016 - 2027)

• Adult Stem Cells (ASCs)

  • Neuronal ASCs

  • Hematopoietic ASCs

  • Mesenchymal ASCs

  • Umbilical Cord ASCs

  • Dental ASCs

  • Adipose‐derived ASCs

  • Dedifferentiated fat (DFAT) Cells

  • Other ASCs

• Human Embryonic Stem Cells

• Induced Pluripotent Stem Cells

• Very Small Embryonic Like Stem Cells

Stem Cells Application Outlook (Revenue, USD Million, 2016 - 2027)

• Regenerative Medicine

  • Neurology

  • Orthopedics

  • Oncology

  • Hematology

  • Cardiovascular and Myocardial Infraction

  • Injuries

  • Diabetes

  • Liver Disorder

  • Incontinence

  • Others

• Drug Discovery and Development

Stem Cells Technology Outlook (Revenue, USD Million, 2016 - 2027)

• Cell Acquisition

  • Bone Marrow Harvest

  • Umbilical Blood Cord

  • Apheresis

• Cell Production

  • Therapeutic Cloning

  • In-vitro Fertilization

  • Cell Culture

  • Isolation

• Cryopreservation

• Expansion and Sub-Culture

Stem Cells Therapy Outlook (Revenue, USD Million, 2016 - 2027)

• Autologous

• Allogenic

Stem Cells Regional Outlook (Revenue, USD Billion, 2016 - 2027)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

• Asia Pacific

  • China

  • Japan

• Latin America

  • Brazil

• Middle East & Africa

  • South Africa